-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cq+hjT2kSwJHVjcwUs1k1My4J/6u6CXH9dQYoroyPXV9UfSLYrNjQLIJNZyQxOpZ N7qnSRkEnSG6LYMWRBZ3Eg== 0000000000-05-003867.txt : 20060310 0000000000-05-003867.hdr.sgml : 20060310 20050126115038 ACCESSION NUMBER: 0000000000-05-003867 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050126 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: PHIBRO ANIMAL HEALTH CORP CENTRAL INDEX KEY: 0001069899 STANDARD INDUSTRIAL CLASSIFICATION: GRAIN MILL PRODUCTS [2040] IRS NUMBER: 131840497 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 65 CHALLENGER ROAD CITY: RIDGEFIELD PARK STATE: NJ ZIP: 07660 BUSINESS PHONE: 201-329-7300 MAIL ADDRESS: STREET 1: 65 CHALLENGER ROAD CITY: RIDGEFIELD PARK STATE: NJ ZIP: 07660 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPP BROTHERS CHEMICALS INC DATE OF NAME CHANGE: 19980908 PUBLIC REFERENCE ACCESSION NUMBER: 0000950123-05-000375 LETTER 1 filename1.txt Via Facsimile and U.S. Mail Mail Stop 03-09 January 26, 2005 Jack C. Bendheim President and Chairman of the Board Phibro Animal Health Corporation 65 Challenger Road Ridgefield Park, New Jersey 07660 Re: Phibro Animal Health Corporation Registration Statement on Form S-4 File No. 333-122063, filed January 14, 2005 Dear Mr. Bendheim: We have limited our review of the above referenced filing to monitor only for confirmation of your reliance on the staff`s position enunciated in Exxon Capital Holdings Corporation, SEC No- Action Letter (May 13, 1988); Morgan Stanley & Co. Incorporated, SEC No-Action Letter (June 5, 1991); and Sherman and Sterling, SEC No- Action Letter (July 2, 1993). Please provide a supplemental letter to the staff (i) stating that you are registering the exchange offer in reliance on the staff`s position contained in these no-action letters, and (ii) including the statements and representations substantially in the form set forth in the Morgan Stanley and Sherman & Sterling no-action letters. Please furnish a cover letter that keys your response to our comment. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your response to our comment. Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter. Notwithstanding our comments, in the event the company requests acceleration of the effective date of the pending registration statement, it should furnish a letter, at the time of such request, acknowledging that: * should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; * the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and * the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in connection with our review of your filing or in response to our comments on your filing. We will consider a written request for acceleration of the effective date of the registration statement as a confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. We will act on the request and, pursuant to delegated authority, grant acceleration of the effective date. We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date. Please direct any questions to Anne Nguyen, Attorney-Advisor, at (202) 942-2895. Sincerely, Jeffrey Riedler Assistant Director cc: Lawrence M. Bell, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP 437 Madison Avenue New York, New York 10022-7302 ?? ?? ?? ?? Jack C. Bendheim Phibro Animal Health Corporation January 26, 2005 Page 1 -----END PRIVACY-ENHANCED MESSAGE-----